Canada markets open in 3 hours 18 minutes

ImmunoGen, Inc. (IMU.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.6235+0.0010 (+0.03%)
As of 08:03AM CEST. Market open.
Full screen
Previous Close3.6225
Open3.6235
Bid3.6585 x 100000
Ask3.7385 x 100000
Day's Range3.6235 - 3.6235
52 Week Range3.3155 - 6.6820
Volume360
Avg. Volume6
Market Cap801.536M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.6500
Earnings DateJul 28, 2022 - Aug 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.79
  • Business Wire

    ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

    WALTHAM, Mass., May 10, 2022--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

  • Motley Fool

    ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript

    With me today are Mark Enyedy, our president and CEO; Anna Berkenblit, our chief medical officer; Kristen Harrington-Smith, our chief commercial officer; and Susan Altschuller, our CFO. As we progress toward our goal of becoming a global fully integrated oncology company, since the start of the year, we've also continued enrollment in the confirmatory Phase III MIRASOL and Phase II PICCOLO studies with mirv monotherapy, expanded our commercial team and accelerated launch preparations in anticipation of a mirv approval, further accrued patients in our pivotal CADENZA study of pivek and BPDCN, initiated expansion cohorts in both relapsed and frontline AML patients combining pivek with azacitidine and venetoclax and progressed our earlier-stage programs, IMGC936 and IMGN151.

  • Zacks

    ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates

    ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?